Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Stroke
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Stroke
    Gastrointestinal Bleeding After Stroke May Increase Risk of Death - (DGNews)
    Telemedicine Improves Accuracy of Stroke Treatment Decisions in Remote Locations - (DGNews)
    Gene May Increase Heart Disease, Stroke Risk in Women With Migraine - (DGNews)
    TopAbstracts in Stroke 07/24/2008 - (DGNews)
    New Guidelines Underline Key Differences Between Child and Adult Stroke - (DGNews)

    News archive

     Recent webcasts/CME - Stroke
    Acute Stroke Therapy for the New Millennium: Does Thrombolytic Work?

    Webcasts/CME archive

     Recent cases - Stroke
      Acute Bilateral Anterior Circulation Stroke Due to Anomalous Cerebral Vasculature: A Case Report
      Evolution of Changes in the Computed Tomography Scans of the Brain of a Patient with Left Middle Cerebral Artery Infarction: A Case Report
      Stroke in Inflammatory Bowel Disease: A Report of Two Cases and Review of the Literature
      Unusual Presentation of Basilar Artery Stroke Secondary to Patent Foramen Ovale: A Case Report
      Circuitous Embolic Hemorrhagic Stroke: Carotid Pseudoaneurysm to Fetal Posterior Cerebral Artery Conduit: A Case Report

      Cases archive
        




      my personal edition > stroke > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Arundic Acid Has Neuroprotective Potential For Treating Ischaemic Stroke: Presented at ANA

      By Paula Moyer

      TORONTO, ON -- October 11, 2004 -- The investigative agent arundic acid is showing potential as a neuroprotective agent for treating patients after ischaemic stroke, according to investigators.

      Presenting study findings here October 5th at the 129th annual meeting of the American Neurological Association, L. Creed Pettigrew, MD, professor of neurology at the University of Kentucky in Lexington, Kentucky, United States, said, "Arundic acid has promise in preventing brain damage after stroke." He continued, "It can be used safely with or without thrombolytics."

      Dr. Pettigrew and his co-investigators were interested in arundic acid because earlier primate studies indicated that the drug was able to reach effective blood levels without increasing the risk of haemorrhage when used with thrombolytics. These criteria are the standard for a post-stroke neuroprotective agent, he said.

      Therefore, they observed the results of arundic acid in 92 patients, 49 of whom received the study drug and 43 of whom received placebo within 24 hours after stroke onset. The patients in the treatment group received 2 to 12 mg/kg/hr. Patients received 8 to 9 courses of treatment for 7 days. The investigators conducted pharmacokinetic profiling on days 1 and 3. For comparison, they also studied the effects in 9 healthy volunteers. Of these, 6 received 10 mg/kg/hour of the study drug, and 3 received placebo.

      The investigators assessed patients' haemostasis before treatment, at the onset of treatment, and 6 hours after treatment. The instruments used included platelet aggregation, the ratio of prothrombin time and activated partial thromboplastic time (PT/aPTT), and whole blood clotting time as calculated by the Ivy method.

      The plasma level of arundic acid that was deemed therapeutic was at least 2 mg/kg per hour. This level was reached in all subjects. Fortunately, 1 hour after infusion of arundic acid, the investigators documented no effect of therapy on either cellular or humoral coagulation. Dr. Pettigrew and his co-investigators reported that they did not have to adjust the dose on any patient, although drug clearance was slightly lower in older subjects who were more than 70 years old.

      The study was funded by the Ono Pharmaceutical Company.

      [Presentation title: Arundic acid in acute ischemic stroke: Pharmacokinetics and coagulation effects. Abstract #125]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send